$ZYNE Major Catalysts ahead ( Q4). new Presentation on Board. Consensus P.T By 5 Analysts is around $21 One of the many drugs in its pipeline is ZYN002, the only cannabidiol gel currently undergoing FDA trials — it has three Phase II studies underway.fully Funded.
Arlinda Lee,PhD Success Rate on Stock 50% https://t.co/9M96hzxwPX "ZYN002 could provide the basis for regulatory approval"..
$ZYNE analyst number 3. CANTOR FITZGERALD We rate 12-month PT of $20/share. Zynerba is developing ZYN002, a synthetic CBD gel to treat neurological conditions. https://t.co/Tv0javh00Thttps://t.co/EHAqaPzXIl
My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.